2 completed, 1 active not recruiting, 1 recruiting, 1 unknown. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Unknown 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
Follow Lymphomatoid Granulomatosis: new trials by email Literature Review of Lymphomatoid Granulomatosis trials Research Report on Lymphomatoid Granulomatosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Nivolumab, Varlilumab - ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 54 | 2018-12-21 | 2026-10-26 |
| Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies XmAb13676 - B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Completed | Xencor, Inc. | 154 | 2016-10-01 | 2024-11-13 |
| Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes Cyclophosphamide or Bendamustine, Dose Level -1, Dose Level 1 - Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Unknown | Jichi Medical University | 18 | 2014-05-01 | 2014-11-06 |
| Tissue Collection for Studies of Lymph Cancer Hodgkin Disease, Lymphoma, Non-Hodgkin | Recruiting | National Cancer Institute (NCI) | 1295 | 2012-09-21 | 2026-10-26 | |
| Treatment and Natural History Study of Lymphomatoid Granulomatosis Interferon, Rituxan and EPOCH, Tumor biopsy - Lymphomatoid Granulomatosis, Granulomatosis, Lymphomatoid | Phase 2 | Completed | National Cancer Institute (NCI) | 94 | 1995-05-05 | 2025-06-19 |
Lymphoma, Non-Hodgkin (4) · Burkitt Lymphoma (3) · Lymphoma, B-Cell (3) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Mantle-Cell (2) · Lymphoma, Primary Effusion (2) · Plasmablastic Lymphoma (2) · Epstein-Barr Virus Infections (1) · Hodgkin Disease (1) · Immune System Diseases (1) · Leukemia (1)
Hemic and Lymphatic Diseases (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Precancerous Conditions (5) · DNA Virus Infections (4) · Herpesviridae Infections (4) · Immune System Diseases (4) · Infections (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Tumor Virus Infections (4) · Virus Diseases (4) · Epstein-Barr Virus Infections (3) · Lymphoma (3)
Cyclophosphamide (2) · Bendamustine Hydrochloride (1) · Caves (1) · Disulfides (1) · Doxorubicin (1) · EPOCH protocol (1) · Echocardiography (1) · Etoposide (1) · Immunoglobulin G (1) · Interferons (1) · Nivolumab (1) · Prednisone (1) · Rituximab (1) · Tomography, X-Ray Computed (1) · Vincristine (1)
National Cancer Institute (NCI) (3) · Jichi Medical University (1) · Xencor, Inc. (1)
United States (4) · France (1) · Jamaica (1) · Japan (1) · South Korea (1) · United Kingdom (1)
Christopher J Melani, M.D. (2) · Chet Bohac, PharmD, MD, MSc (1) · Keiya Ozawa, MD, PhD (1) · Stephen M Ansell (1)
UM1CA186686 (1), UM1CA186709 (1)